A new breast cancer drug could give sufferers “more precious time with their loved ones” a charity has said, as it welcomed a decision to approve it for use on the Scottish NHS.
On Monday, sacituzumab govitecan was approved by the Scottish Medicines Consortium for use in the health service for patients with triple negative cancer – a aggressive form of the disease which often affects younger women.
